Abstract
We have used the effect of therapeutic agents on clonogenic growth in agar to discriminate between active and inactive agents for malignant melanoma. We report a prospective study of single-agent chemotherapy for metastatic melanoma. Forty-five separate in vitro/in vivo correlative trials were conducted in 34 patients. A number of agents were used in these evaluations, including actinomycin D, Amsacrine, bisantrene, mitoxantrone, BCNU, vinblastine, vindesine, 5-fluorouracil, MGBG, etoposide, interferon, tamoxifen, and 13-cis-retinoic acid. At the 'cut-off' concentration, a colony survival <30% was designated as 'sensitivity' and >30% as 'resistance'. Clinical sensitivity was designated to include complete, partial, and mixed responses and was predicted in eight of 18 trials (44%). Clinical resistance (nonresponse) was predicted correctly in 24 of 27 cases (89%). Using Fisher's exact test the association of in vitro and in vivo results was significant (P=.05). These results offer further support for the concept that clonogenic assays may help select useful agents for clinical trials in metastatic melanoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1223-1228 |
| Number of pages | 6 |
| Journal | Journal of Clinical Oncology |
| Volume | 2 |
| Issue number | 11 |
| State | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. / Meyskens, F. L.; Loescher, Lois J; Moon, T. E.; Takasugi, B.; Salmon, S. E.
In: Journal of Clinical Oncology, Vol. 2, No. 11, 1984, p. 1223-1228.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma
AU - Meyskens, F. L.
AU - Loescher, Lois J
AU - Moon, T. E.
AU - Takasugi, B.
AU - Salmon, S. E.
PY - 1984
Y1 - 1984
N2 - We have used the effect of therapeutic agents on clonogenic growth in agar to discriminate between active and inactive agents for malignant melanoma. We report a prospective study of single-agent chemotherapy for metastatic melanoma. Forty-five separate in vitro/in vivo correlative trials were conducted in 34 patients. A number of agents were used in these evaluations, including actinomycin D, Amsacrine, bisantrene, mitoxantrone, BCNU, vinblastine, vindesine, 5-fluorouracil, MGBG, etoposide, interferon, tamoxifen, and 13-cis-retinoic acid. At the 'cut-off' concentration, a colony survival <30% was designated as 'sensitivity' and >30% as 'resistance'. Clinical sensitivity was designated to include complete, partial, and mixed responses and was predicted in eight of 18 trials (44%). Clinical resistance (nonresponse) was predicted correctly in 24 of 27 cases (89%). Using Fisher's exact test the association of in vitro and in vivo results was significant (P=.05). These results offer further support for the concept that clonogenic assays may help select useful agents for clinical trials in metastatic melanoma.
AB - We have used the effect of therapeutic agents on clonogenic growth in agar to discriminate between active and inactive agents for malignant melanoma. We report a prospective study of single-agent chemotherapy for metastatic melanoma. Forty-five separate in vitro/in vivo correlative trials were conducted in 34 patients. A number of agents were used in these evaluations, including actinomycin D, Amsacrine, bisantrene, mitoxantrone, BCNU, vinblastine, vindesine, 5-fluorouracil, MGBG, etoposide, interferon, tamoxifen, and 13-cis-retinoic acid. At the 'cut-off' concentration, a colony survival <30% was designated as 'sensitivity' and >30% as 'resistance'. Clinical sensitivity was designated to include complete, partial, and mixed responses and was predicted in eight of 18 trials (44%). Clinical resistance (nonresponse) was predicted correctly in 24 of 27 cases (89%). Using Fisher's exact test the association of in vitro and in vivo results was significant (P=.05). These results offer further support for the concept that clonogenic assays may help select useful agents for clinical trials in metastatic melanoma.
UR - http://www.scopus.com/inward/record.url?scp=0021687248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021687248&partnerID=8YFLogxK
M3 - Article
VL - 2
SP - 1223
EP - 1228
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 11
ER -